Premium
Differentiation of equine mesenchymal stromal cells into neural cells: potential for clinical applications (596.4)
Author(s) -
Cruz Villagran Claudia,
Amelse Lisa,
Neilsen Nancy,
Dhar Madhu
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.596.4
Subject(s) - nestin , mesenchymal stem cell , vimentin , microbiology and biotechnology , biology , stromal cell , progenitor cell , lineage markers , bone marrow , pathology , neural stem cell , cancer research , immunology , stem cell , immunohistochemistry , medicine
Peripheral nerve injuries cause poor performance in horses. They are difficult to manage and clinicians mostly rely upon physical therapy and anti‐inflammatories. The long term effects are time and personnel consuming. The aim of this research is to test the ability of equine mesenchymal stromal cells (MSCs) to differentiate into neuronal lineage, and trans‐differentiate into Schwann cells for nerve regeneration. Bone marrow‐derived MSCs were obtained from 3 young and 4 adult horses. Firstly, their stemness was demonstrated. Low passaged cells were neuronally induced in 24 well plates and assessed by microscopy at 3, 6, 12, 24 and 48 h. Results showed that the plate PRIMARIA™ supported proliferation and differentiation. Survival was improved by high number of cells. Morphological changes were observed as early as 3 hours; at 12 h approximately 60% of the cells were neuron‐like. Morphology was similar in all horses, but proliferation was variable. Protein concentration was influenced by cell number and method of protein extraction. Expression of neuronal progenitor proteins, vimentin, β3 tubulin and GFAP, was detected by immunoblot analysis; nestin was not evident. Results demonstrate that equine MSCs can differentiate into neuronal lineage. Future work is aimed to commit these cells into Schwann cells. Expression of additional neural‐specific markers, S100B, Krox20 and CD104 will be tested.